Treating patients with venous thromboembolism: Initial strategies and long-term secondary prevention

Seminars in Vascular Medicine

Volumn 5, Issue 3, 2005, Pages 276-284

  Huisman, Menno V ^a   Bounameaux, Henri ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Low molecular weight heparin; Oral anticoagulation; Synthetic pentasaccharides; THRIVE; Venous thromboembolism treatment and secondary prevention; Ximelagatran

Indexed keywords

ACENOCOUMAROL; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; PATIENT MONITORING; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIVER DISEASES; MYOCARDIAL ISCHEMIA; OLIGOSACCHARIDES; POLYSACCHARIDES; RECURRENCE; THROMBIN; TIME FACTORS; VENOUS THROMBOSIS; WARFARIN;

EID: 24144446705     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916167     Document Type: Review

References (46)

1. Hawkins D. Pharmacoeconomics of thrombosis management. Pharmacotherapy 2004;24:95S-99S
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938
4. Turpie AG, Chin BS, Lip GY. ABC of antithrombotic therapy: venous thromboembolism: treatment strategies. BMJ 2002;325:948-950
5. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S
6. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-240
7. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society Lancet 1992;340:873-876
8. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332: 1661-1665
9. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-611
10. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-398
11. Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coagul Fibrinolysis 1996;7: 507-514
12. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907
13. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-979
14. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99
15. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998;13:311-316
16. Ageno W, Huisman MV. Low-molecular-weight heparins in the treatment of venous thromboembolism. Curr Control Trials Cardiovasc Med 2000;1:102-105
17. Warkentin TE. Heparin-induced thrombocytopenia. Curr Hematol Rep 2002;1:63-72
18. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17
19. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
20. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304
21. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607
22. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277
23. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41: 1633-1652
24. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991;115:591-595
25. Wong JE. Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treat Rev 2003;29(Suppl 2):11-13
26. Kakkar AK, Davidson BL, Haas SK. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004;2:221-227
27. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
28. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
29. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639
30. Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702
31. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873
32. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004;2:47-53
33. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H,THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349: 1713-1721
34. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689
35. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-248
36. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
37. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083
38. Huisman MV, van der Meer FJ, van Rooden CJ, Prins MH. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:2164-2167
39. Giangrande PL. Fondaparinux (Arbitra): a new anticoagulant. Int J Clin Pract 2002;56:615-617
40. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004;110:I19-I26
41. Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med 2004;10:338-344
42. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003;109: 1-11
43. Gustafsson D, Bylund R, Antonsson T, et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004;3:649-659
44. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005;28:351-370
45. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797
46. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Cardiovascular and renal drugs advisory committee meeting. New Drug Application (NDA) 21-686, proposed trade name Exanta (ximelagatran) by AstraZeneca. Available at: http:// www.fda.gov/ohrms/ dockets/ac/04/transcripts/2004-4069T1. htm. Accessed August 1, 2005